Sex | | Comorbids | |
Male | 1050 (21.0) | Hepatic disorder | 4846 (96.9) |
Female | 3950 (79.0) | None | |
Age | | Yes | 154 (3.1) |
⩽29 years | 260 (5.2) | Cardiac disorder | |
30–39 years | 355 (7.1) | None | 4874 (97.5) |
40–49 years | 723 (14.5) | Yes | 126 (2.5) |
50–59 years | 1656 (33.1) | Diabetes mellitus | |
60–69 years | 1434 (28.7) | None | 4532 (90.6) |
70 years⩽ | 572 (11.4) | Yes | 468 (9.4) |
Mean (SD) (years) | 55.1 (12.9) | Respiratory disease | |
Steinbrocker stage classification | | None | 4765 (95.3) |
I | 272 (5.4) | Yes | 235 (4.7) |
II | 1150 (23.0) | Haematological disease | |
III | 1812 (36.2) | None | 4938 (98.8) |
IV | 1766 (35.3) | Yes | 62 (1.2) |
Steinbrocker functional classification | | Allergy | |
I | 411 (8.2) | None | 4369 (89.1) |
II | 2784 (55.7) | Yes | 537 (10.9) |
III | 1619 (32.4) | Unknown | 94 |
IV | 186 (3.7) | History of tuberculosis infection | |
Duration of rheumatoid arthritis | | None | 4742 (94.8) |
<3 years | 882 (18.4) | Yes | 258 (5.2) |
3–5 years | 612 (12.8) | Methotrexate dose | |
5–10 years 10–15 years | 1287 (26.9)894 (18.7) | <6 mg/week6–8mg/week | 121 (2.4)4338 (86.8) |
15 years⩽ | 1111 (23.2) | 8 mg/week< | 541 (10.8) |
Unknown | 214 | Mean (SD) (mg/week) | 7.3 (2.0) |
Mean (SD) (years) | 9.9 (8.1) | Serum creatinine | |
Body weight | | <1.0 mg/dL | 4871 (97.4) |
<40 kg | 245 (4.9) | 1.0 mg/dL ⩽ | 128 (2.6) |
40–50 kg | 1447 (29.0) | Unknown | 1 |
50–60 kg | 1978 (39.6) | Concomitant glucocorticosteroid | |
60–70 kg | 962 (19.3) | None | 583 (11.7) |
70 kg⩽ | 358 (7.2) | Yes | 4417 (88.3) |
Unknown | 10 | Participating to infliximab clinical trials | |
Mean (SD) (kg) | 53.9 (10.1) | None | 4948 (99.0) |
| | Yes | 52 (1.0) |